Cellectis S.A. (NASDAQ: CLLS)
$2.16
+0.0700 ( +3.35% ) 40.5K
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
Market Data
Open
$2.16
Previous close
$2.09
Volume
40.5K
Market cap
$217.20M
Day range
$2.09 - $2.27
52 week range
$0.96 - $3.77
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
20-f/a | Annual reports | 16 | Oct 31, 2023 |
6-k | Quarterly Reports | 2 | Oct 31, 2023 |
6-k | Quarterly Reports | 2 | Oct 24, 2023 |
6-k | Quarterly Reports | 2 | Oct 12, 2023 |
6-k | Quarterly Reports | 2 | Sep 27, 2023 |
6-k/a | Quarterly Reports | 112 | Sep 05, 2023 |
6-k | Quarterly Reports | 2 | Aug 07, 2023 |
6-k | Quarterly Reports | 2 | Aug 07, 2023 |
6-k | Quarterly Reports | 2 | Aug 03, 2023 |
6-k | Quarterly Reports | 2 | Jul 27, 2023 |